https://www.selleckchem.com/pr....oducts/dl-ap5-2-apv.
© 2020 WILEY-VCH Verlag GmbH Co. KGaA, Weinheim.OBJECTIVES To report interim data from TAURUS, a study assessing real-world prophylactic treatment with unmodified, full-length recombinant FVIII BAY 81-8973 (Kovaltry® , Bayer) indicated for haemophilia A. METHODS TAURUS (NCT02830477) is an international, open-label, prospective, non-interventional, single-arm study with a one-year observation period (target N = 35. Patients have moderate or severe haemophilia A (FVIII ≤5% or ≤1%) and ≥50 exposure days to any FVIII product. C
Like
Comment
Share
